Company intelligence / Profile preview

Arvid Carlsson Research AB

Stockholm, Stockholm, Swedenresearchgate.net ↗

Ownership: Private
Development stage: Phase 3

Overview

As of March 2025, the company has one drug (OSU6162) in Phase 2 clinical trials for post-stroke fatigue. A Phase 2 randomized, placebo-controlled, two-armed study comparing 16-week OSU6162 treatment to placebo in patients with residual symptoms following stroke[2].

Therapeutic areas: PsychiatryDermatologyNeurologyInfectious Diseases
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

5 assets

mesdopetam

Phase 3

Indications: Parkinson's disease levodopa-induced dyskinesias

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Arvid Carlsson Research AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arvid Carlsson Research AB.

Explore the full profile